Business Description
Brii Biosciences Ltd
ISIN : KYG1645A1094
Share Class Description:
FRA:7SS: Ordinary SharesTotal Employee Number:
75Compare
Compare
Traded in other countries / regions
02137.Hong KongBRIBF.USA7SS.Germany IPO Date
2021-07-19Description
Brii Biosciences Ltd is a biotechnology company based in China and the United States. It is committed to developing advancing therapies for infectious diseases, such as HBV, HIV, MDR/XDR gram-negative infections, and other illnesses, such as CNS diseases, which haveĀ public health burdens in China and around the world. The company's pipeline of products includes more than 10 product candidates that focus onĀ infectious diseases and mental illnesses.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 217.22 | |||||
Equity-to-Asset | 1.01 | |||||
Debt-to-EBITDA | -0.04 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 6.53 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -29.5 | |||||
3-Year EBITDA Growth Rate | 23.3 | |||||
3-Year EPS without NRI Growth Rate | 23.4 | |||||
3-Year FCF Growth Rate | 10.1 | |||||
3-Year Book Growth Rate | -9.5 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 36.4 | |||||
9-Day RSI | 39.93 | |||||
14-Day RSI | 40.42 | |||||
3-1 Month Momentum % | -18.88 | |||||
6-1 Month Momentum % | -22.15 | |||||
12-1 Month Momentum % | -37.3 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 60.73 | |||||
Quick Ratio | 60.73 | |||||
Cash Ratio | 60.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 0.3 | |||||
Shareholder Yield % | 5.16 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -1531.67 | |||||
Net Margin % | -1188.2 | |||||
EBITDA Margin % | -1148.12 | |||||
FCF Margin % | -2495.7 | |||||
OCF Margin % | -1816 | |||||
ROE % | -8.96 | |||||
ROA % | -8.92 | |||||
ROIC % | -74.55 | |||||
3-Year ROIIC % | 3458.28 | |||||
ROC (Joel Greenblatt) % | -1098.9 | |||||
ROCE % | -9.01 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 32.76 | |||||
PB Ratio | 0.26 | |||||
Price-to-Tangible-Book | 0.3 | |||||
EV-to-EBIT | 6.63 | |||||
EV-to-EBITDA | 6.79 | |||||
EV-to-Revenue | -77.91 | |||||
EV-to-FCF | 3.14 | |||||
| Price-to-Net-Current-Asset-Value | 0.32 | |||||
| Price-to-Net-Cash | 0.32 | |||||
Earnings Yield (Greenblatt) % | 15.08 | |||||
FCF Yield % | -74.52 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Ā
Total Annual Return % Ā
Brii Biosciences Ltd Executives
DetailsGF Valueā¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ā¬) | 2.256 | ||
| EPS (TTM) (ā¬) | -0.037 | ||
| Beta | 0.7953 | ||
| 3-Year Sharpe Ratio | -0.28 | ||
| 3-Year Sortino Ratio | -0.44 | ||
| Volatility % | 43.3 | ||
| 14-Day RSI | 40.42 | ||
| 14-Day ATR (ā¬) | 0.008453 | ||
| 20-Day SMA (ā¬) | 0.10655 | ||
| 12-1 Month Momentum % | -37.3 | ||
| 52-Week Range (ā¬) | 0.0955 - 0.262 | ||
| Shares Outstanding (Mil) | 721.18 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Brii Biosciences Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Brii Biosciences Ltd Stock Events
| Event | Date | Price (ā¬) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2026 | 2026-08-21 18:30 | In 54 days | ||
| Second quarter earnings results for 2026 | 2026-08-21 | In 53 days | ||
| General meeting for 2025 | 2026-06-16 08:00 | 0.10 (-14.29%) | ||
| Annual report for 2025 | 2026-04-23 | 0.16 (+1.29%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-20 08:30 | 0.15 (-1.95%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-19 | 0.16 (+0.00%) | ||
| Second quarter earnings conference call for 2025 | 2025-08-21 18:30 | 0.21 (-2.75%) | ||
| Second quarter earnings results for 2025 | 2025-08-21 | 0.21 (-2.75%) | ||
| General meeting for 2024 | 2025-06-03 09:00 | 0.20 (+0.00%) | ||
| Annual report for 2024 | 2025-04-25 | 0.20 (+2.58%) |
Show
Entries
Brii Biosciences Ltd Frequently Asked Questions
What is Brii Biosciences Ltd(FRA:7SS)'s stock price today?
The current price of FRA:7SS is ā¬0.10. The 52 week high of FRA:7SS is ā¬0.26 and 52 week low is ā¬0.10.
When is next earnings date of Brii Biosciences Ltd(FRA:7SS)?
The next earnings date of Brii Biosciences Ltd(FRA:7SS) is 2026-08-21 Est..
Does Brii Biosciences Ltd(FRA:7SS) pay dividends? If so, how much?
Brii Biosciences Ltd(FRA:7SS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Brii Biosciences Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers